<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00964730</url>
  </required_header>
  <id_info>
    <org_study_id>TAL-TQT-101</org_study_id>
    <secondary_id>R09-0539</secondary_id>
    <nct_id>NCT00964730</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm</brief_title>
  <official_title>A Phase I, Single-Center, Double-Blind, Randomized, Placebo- and Positive- Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Talampanel on Cardiac Repolarization in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cetero Research, San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Teva Branded Pharmaceutical Products R&amp;D, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether multiple doses of Talampanel increase the QT&#xD;
      interval when compared to placebo&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effects of Talampanel on cardiac repolarization after multiple therapeutic doses administered over 10 days</measure>
    <time_frame>12 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Examine the PK profile of talampanel and its metabolite -Assess the PK/PD relationship of the time course of QT/QTc interval prolongation-Assess the safety and tolerability of multiple doses of talampanel in healthy volunteers</measure>
    <time_frame>12 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Talampanel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talampanel</intervention_name>
    <description>titrated to 50mg three times a day over 9 days and a single dose administered on Day 10</description>
    <arm_group_label>Talampanel</arm_group_label>
    <other_name>TV-7600, GYKI 53773</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10</description>
    <arm_group_label>Moxifloxacin</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>administered three times a day over 9 days and a single dose administered on Day 10</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers aged 18 to 50 years of age inclusive.&#xD;
&#xD;
          -  Body mass index: Between 18 and 30 kg/m2 and weight of at least 50 kg.&#xD;
&#xD;
          -  Female volunteers must have either a negative pregnancy test and be willing to use&#xD;
             birth control, be post-menopausal evidenced by lab test, or be surgically sterile.&#xD;
&#xD;
          -  Volunteers must be able to understand the requirements of the study and must be&#xD;
             willing to comply with the requirements of the study and provide their written&#xD;
             informed consents to participate in the study prior to the conduct of study&#xD;
             procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male and female volunteers with a resting QT interval of &lt; 320 msec or &gt; 450 msec&#xD;
             (males) or &gt; 470 msec (females&#xD;
&#xD;
          -  Volunteers with ECG abnormalities that may interfere with the accurate assessment of&#xD;
             the QT interval&#xD;
&#xD;
          -  Volunteers with known cardiovascular disorders, including coronary artery disease,&#xD;
             valvular heart disease, cardiomyopathies, or ECG abnormalities suggestive of prior&#xD;
             myocardial infarction, chamber enlargement or hypertrophy.&#xD;
&#xD;
          -  Volunteers with known clinically significant arrhythmias or rhythm disturbances&#xD;
             observed on ECG&#xD;
&#xD;
          -  Volunteers who have a history of, or risk factors for, Torsades de Pointes (e.g. heart&#xD;
             failure, abnormal serum electrolytes), including a history of family history of&#xD;
             arrhythmia, sudden death, long QT syndrome, Brugada complex, or personal history of&#xD;
             syncope.&#xD;
&#xD;
          -  Volunteers who have a heart rate outside 40-90 beats per minute&#xD;
&#xD;
          -  Volunteers who have a blood pressure outside 90-140 mmHg systolic or 45-90 mmHg&#xD;
             diastolic&#xD;
&#xD;
          -  Volunteers with history of uncontrolled hypertension, impaired glucose tolerance,&#xD;
             diabetes mellitus, kidney disease, edema, stroke or neurological disorder,&#xD;
             rheumatological disorder, lung disease, heart disease, liver disease, or a history of&#xD;
             any illness that pose additional risk to the volunteer&#xD;
&#xD;
          -  Volunteers with a history of psychiatric disorders, including bipolar disorder,&#xD;
             psychosis, previous episode(s) of major depression, history of suicidality or suicidal&#xD;
             ideation.&#xD;
&#xD;
          -  Volunteers who have history of surgeries or conditions that affect the way drugs are&#xD;
             absorbed or distributed in the body such as intestinal surgery, stomach surgery.&#xD;
&#xD;
          -  Volunteers with impaired liver function and elevated liver enzymes&#xD;
&#xD;
          -  Volunteers with major trauma or surgery in the past 2 months, acute infection within 2&#xD;
             weeks, cancer within the last 5 years (excluding non-melanoma skin cancers), History&#xD;
             of tuberculosis, abnormal lab tests&#xD;
&#xD;
          -  Female volunteers who are lactating or intend to become pregnant during the study&#xD;
             period.&#xD;
&#xD;
          -  Volunteers with a known allergy or sensitivity to moxifloxacin or its derivatives,&#xD;
             benzodiazepines, talampanel or its derivatives, or any contraindications to&#xD;
             moxifloxacin, benzodiazepines, or talampanel.&#xD;
&#xD;
          -  Volunteers with significant food or drug allergies&#xD;
&#xD;
          -  Volunteers that have used an investigational drug (new chemical entity) 3 months prior&#xD;
             to the start of the study,.who have consumed any medications (including&#xD;
             over-the-counter medications, prescription medications, investigational drugs,&#xD;
             vitamins, or herbal remedies) within 30 days prior to check-in (with the exception of&#xD;
             hormonal contraceptives [females only] and occasional use of acetaminophen and&#xD;
             ibuprofens, who have consumed amiodarone and chloroquine within 4 months prior to&#xD;
             screening, who have consumed excessive amounts of alcohol or are unwilling to comply&#xD;
             with the restricted use of alcohol during the study, who have consumed excessive&#xD;
             amounts of coffee, tea, coke, or other caffeinated beverages within 2 weeks prior to&#xD;
             check-in, who have consumed quinine (tonic water) within 7 days prior to study start,&#xD;
             who have consumed grapefruit, grapefruit juice, or Seville orange juice within the 7&#xD;
             days prior to study start, who smoke, have smoked in the last 3 months, or are&#xD;
             planning to start smoking during the study, tobacco users, subjects currently using&#xD;
             nicotine products, or subjects with a positive urine cotinine test at study start&#xD;
&#xD;
          -  Volunteers who are currently regular users (including recreational use) of any illicit&#xD;
             drugs or who have a history of drug (including alcohol) abuse within 1 year of study&#xD;
             start.&#xD;
&#xD;
          -  Volunteers with positive urine test for drugs of abuse at screening or check-in.&#xD;
&#xD;
          -  Volunteers who have donated or received any blood, plasma, or platelet transfusions in&#xD;
             the 3 months prior to study start, or who have made donations on more than two&#xD;
             occasions within the 12 months preceding the first dose administration, or who have&#xD;
             planned donations during the study or during the 3 months following the study.&#xD;
&#xD;
          -  Volunteers with a positive screening test for Hepatitis B, Hepatitis C or HIV&#xD;
&#xD;
          -  Volunteers not willing to refrain from changing level of activity during the study and&#xD;
             from jogging and strenuous exercise of all types while at the research unit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig R Sprenger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research - Fargo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cetero Research - Fargo</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>August 21, 2009</study_first_submitted>
  <study_first_submitted_qc>August 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2009</study_first_posted>
  <last_update_submitted>April 6, 2010</last_update_submitted>
  <last_update_submitted_qc>April 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Siyu Liu, M.D., Ph.D. VP</name_title>
    <organization>Teva Neuroscience, Inc</organization>
  </responsible_party>
  <keyword>Thorough QT Study</keyword>
  <keyword>Talampanel</keyword>
  <keyword>Cardiac Repolarizatiom</keyword>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

